Other studies have also suggested that pemigatinib-induced G1 arrest is a common cytostatic mechanism across various FGFR expression patterns and tumor types [28], targeting pathways such as PI3K/AKT and RAF/MEK/ERK which are involved in cell growth, migration, proliferation, and metabolism [29,30]. The gene discussed is MAP2K7; the disease is neoplasm.